Induction of ADAM10 Drives Fibrosis and Therapeutic Resistance in Response to SBRT in Pancreatic Ductal Adenocarcinoma

International Journal of Radiation Oncology Biology Physics - Netherlands
doi 10.1016/j.ijrobp.2019.06.280
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Reply To: Relationship Between LAT1 Expression and Resistance to Chemotherapy in Pancreatic Ductal Adenocarcinoma

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma

Cell Reports
BiochemistryGeneticsMolecular Biology
2018English

Fibrosis-Related miRNAs as Serum Biomarkers for Pancreatic Ductal Adenocarcinoma

Oncotarget
Oncology
2017English

The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma

Diseases
2018English

Non-Coding RNAs in Pancreatic Ductal Adenocarcinoma

Frontiers in Oncology
Cancer ResearchOncology
2020English

A Thrombin-Activated PAR-1 Pathway Drives Pancreatic Ductal Adenocarcinoma (PDAC) Growth and Metastasis

Journal of Purdue Undergraduate Research
2019English

Tumor-Stroma Interactions in Pancreatic Ductal Adenocarcinoma

Molecular Cancer Therapeutics
Cancer ResearchOncology
2007English

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)

International Journal of Medical Sciences
Medicine
2020English

Clinical Significance of MUC13 in Pancreatic Ductal Adenocarcinoma

HPB
HepatologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy